Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab).

about

Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab).

Item

http://www.wikidata.org/entity/Q55384914

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab).

@en

Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A

@nl

type

Item

label

Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab).

@en

Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A

@nl

prefLabel

Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab).

@en

Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A

@nl

P1476

Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab).

@en

P2093

Akhila N W Kuda-Wedagedara

http://www.w3.org/2001/XMLSchema#string

Anson Ku

http://www.w3.org/2001/XMLSchema#string

Brooke N McKnight

http://www.w3.org/2001/XMLSchema#string

Dakshnamurthy Selvakumar

http://www.w3.org/2001/XMLSchema#string

Dalya Abdel-Atti

http://www.w3.org/2001/XMLSchema#string

Kuntal K Sevak

http://www.w3.org/2001/XMLSchema#string

Nerissa T Viola-Villegas

http://www.w3.org/2001/XMLSchema#string

Sean D Carlin

http://www.w3.org/2001/XMLSchema#string

Wendy N Wiesend

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting of erbB3 receptor to overcome resistance in cancer treatment

A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies

Expression of the c-erbB-3 protein in normal human adult and fetal tissues

Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.

Standardized methods for the production of high specific-activity zirconium-89.

Phase 1 Evaluation of [(64)Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors.

PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.

ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-RG7116

Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

P304

9043

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-018-27454-6

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jason S. Lewis

P577

2018-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29899472

http://www.w3.org/2001/XMLSchema#string

P932

5998059

http://www.w3.org/2001/XMLSchema#string